ArticleFrontiers in nutrition2025
Association of cardiovascular-kidney-metabolic syndrome with depression and all-cause mortality: a population-based observational study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From conceptual emergence to multidisciplinary expansion: a bibliometric and knowledge mapping analysis of cardiovascular-kidney-metabolic syndrome research.Frontiers in endocrinology · 2026Pooled it
- Depression and risk of incident heart diseases among older adults at CKM stages 0-3: evidence from the China Health and Retirement Longitudinal Study.Annals of medicine · 2026Article
- A machine learning-derived aging index for risk stratification and mortality prediction in cardiovascular-kidney-metabolic syndrome: A retrospective cohort study.PLoS medicine · 2026Article
- Association of the cardiometabolic index and depressive symptoms with cardiovascular disease in cardiovascular-kidney-metabolic syndrome stages 0-3: A prospective cohort study.Scientific reports · 2026Article
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- Association of CTI and its obesity-related derivatives with incident depression among middle-aged and older adults across CKM stages 0-4: a nationwide prospective cohort study and external clinical validation.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular-Kidney-Metabolic Syndrome (CKM) is a novel multi-system disease defined by the American Heart Association (AHA). This study aims to investigate the prevalence of depression in different stages of CKM syndrome and its relationship with the risk of all-cause mortality in patients with depression. Methods: The data used for this study were sourced from the National Health and Nutrition Examination Survey (NHANES) and the National Death Index (NDI) database, which were conducted from 2005 to 2020. CKM syndrome was classified into stages 0-4, among which stages 3-4 were defined as advanced CKM syndrome. Depression was defined according to the Patient Health Questionnaire - 9 (PHQ-9). Multivariable logistic regression and multivariable Cox regression were performed as the main analytical methods. Age-standardized prevalence analysis among four groups and Kaplan-Meier survival analysis were also carried out. Finally, a stratified analysis was conducted. Results: A total of 15,156 participants were included in this study, with a median age of 49 years, among whom 7,608 (50%) were males. The numbers of participants in stages 0-4 of CKM were 1,360, 3,029, 8,246, 842, and 1,679, respectively. The age-standardized prevalence rates of depression in each stage were 3.40, 5.63, 7.44, 16.48, and 18.49%, respectively. In the process of logistic regression, all confounding variables were adjusted for comparison with the participants in stage 0 of CKM syndrome. It was revealed that the prevalence rates of depression in the participants of stage 1, stage 2, and stage 3 did not increase significantly (all Conclusion: Our study shows that the risk of depression increases across stages 0-4 of CKM syndrome. The prevalence of depression in advanced CKM syndrome is also significantly elevated. Moreover, advanced CKM syndrome further increases the risk of all-cause mortality in patients with depression. These findings suggest that medical workers should be vigilant about the mental status of patients with advanced CKM syndrome and the risk of poor prognosis when it is complicated by depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.